The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Lysodren     1-chloro-4-[2,2-dichloro-1- (2...

Synonyms: mitotane, Chloditan, Khloditan, Mytotan, Chlodithane, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Chlodithane


Psychiatry related information on Chlodithane

  • Eighteen months later, however, lethargy and logopathy appeared and the tumor grew again rapidly with the withdrawal of o,p'-DDD performed for the evaluation of these mental disturbances [6].

High impact information on Chlodithane

  • Does mitotane reduce endogenous ACTH secretion [7]?
  • Because of these reports of good results, a phase II trial that used CDDP with and without mitotane (o,p'DDD) was initiated [8].
  • CONCLUSIONS: Mitotane increased SHBG/CBG gene expression and liver production by mechanisms requiring the presence of ERalpha [9].
  • Fourteen patients without distant metastases (World Health Organization stage I, one patient; stage II, seven; stage III, three; and stage IV, three) were matched with 14 patients for resection status, adjuvant mitotane treatment, stage, and tumor size [10].
  • In the HepG2 cell line, 17beta-estradiol (E2) or o,p'-DDD treatment had no effect on mRNA or SHBG/CBG concentrations [9].

Chemical compound and disease context of Chlodithane


Biological context of Chlodithane

  • Transient transfection experiments in Hep89 cells showed that E2 or o,p'-DDD treatment did not increase the transcriptional activity of the minimal proximal promoter of human SHBG gene [9].
  • Prolonged bleeding time due to mitotane therapy [15].
  • In support of a study to develop mitotane analogs as more effective therapeutic agents and as a basis for understanding the toxicity of related compounds in the adrenals, the biotransformations of o,p'-DDD in adrenocortical homogenate preparations have been studied and compared with those of its m,p'- and p,p'-isomers [16].
  • 3. Chemical ADX performed with mitotane (a drug that reduces corticosteroid synthesis) produced essentially the same up-regulation of B(1) receptors as that observed in ADX rats [17].
  • Before and 1 and 2 or more weeks after starting mitotane we determined the platelet counts, bleeding times and global coagulation parameters [15].

Anatomical context of Chlodithane


Associations of Chlodithane with other chemical compounds


Gene context of Chlodithane


Analytical, diagnostic and therapeutic context of Chlodithane


  1. Mitotane therapy of adrenocortical carcinoma. Haak, H.R., van Seters, A.P., Moolenaar, A.J. N. Engl. J. Med. (1990) [Pubmed]
  2. Mitotane. Spironolactone antagonism in Cushing's syndrome. Wortsman, J., Soler, N.G. JAMA (1977) [Pubmed]
  3. Cytotoxic activity of 1-(o-chlorophenyl)-1-(p-chlorophenyl)-2,2-dichloroethane (mitotane) and its analogs on feminizing adrenal neoplastic cells in culture. Fang, V.S. Cancer Res. (1979) [Pubmed]
  4. Long-term (15 years) outcome in an infant with metastatic adrenocortical carcinoma. De León, D.D., Lange, B.J., Walterhouse, D., Moshang, T. J. Clin. Endocrinol. Metab. (2002) [Pubmed]
  5. Low-dose monitored mitotane treatment achieves the therapeutic range with manageable side effects in patients with adrenocortical cancer. Terzolo, M., Pia, A., Berruti, A., Osella, G., Alì, A., Carbone, V., Testa, E., Dogliotti, L., Angeli, A. J. Clin. Endocrinol. Metab. (2000) [Pubmed]
  6. Adrenocortical carcinoma responded to treatment with o,p'-DDD--a case report. Naruse, T., Koike, A., Kato, K., Ishii, T., Suzumura, K., Matsumoto, K. Endocrinol. Jpn. (1984) [Pubmed]
  7. Does mitotane reduce endogenous ACTH secretion? Takamatsu, J., Kitazawa, A., Nakata, K., Furukawa, K., Nakai, Y. N. Engl. J. Med. (1981) [Pubmed]
  8. Phase II trial of mitotane and cisplatin in patients with adrenal carcinoma: a Southwest Oncology Group study. Bukowski, R.M., Wolfe, M., Levine, H.S., Crawford, D.E., Stephens, R.L., Gaynor, E., Harker, W.G. J. Clin. Oncol. (1993) [Pubmed]
  9. Mitotane has an estrogenic effect on sex hormone-binding globulin and corticosteroid-binding globulin in humans. Nader, N., Raverot, G., Emptoz-Bonneton, A., Déchaud, H., Bonnay, M., Baudin, E., Pugeat, M. J. Clin. Endocrinol. Metab. (2006) [Pubmed]
  10. Efficacy of adjuvant radiotherapy of the tumor bed on local recurrence of adrenocortical carcinoma. Fassnacht, M., Hahner, S., Polat, B., Koschker, A.C., Kenn, W., Flentje, M., Allolio, B. J. Clin. Endocrinol. Metab. (2006) [Pubmed]
  11. Twelve-hour cycles of adrenocorticotropin and cortisol secretion in Cushing's disease. Schteingart, D.E., McKenzie, A.K. J. Clin. Endocrinol. Metab. (1980) [Pubmed]
  12. Inhibition of cholesterol oxidase in a patient with Cushing's syndrome. Davey, D.D., Alber, D.B., Ryder, K.W., Jones, J.M., Hostetler, M.L., Moorehead, W.R., Oei, T.O. Clin. Chem. (1984) [Pubmed]
  13. Etoposide, doxorubicin and cisplatin plus mitotane in the treatment of advanced adrenocortical carcinoma: a large prospective phase II trial. Berruti, A., Terzolo, M., Sperone, P., Pia, A., Casa, S.D., Gross, D.J., Carnaghi, C., Casali, P., Porpiglia, F., Mantero, F., Reimondo, G., Angeli, A., Dogliotti, L. Endocr. Relat. Cancer (2005) [Pubmed]
  14. Expression of P-glycoprotein in relation to clinical manifestation, treatment and prognosis of adrenocortical cancer. Haak, H.R., van Seters, A.P., Moolenaar, A.J., Fleuren, G.J. Eur. J. Cancer (1993) [Pubmed]
  15. Prolonged bleeding time due to mitotane therapy. Haak, H.R., Caekebeke-Peerlinck, K.M., van Seters, A.P., Briët, E. Eur. J. Cancer (1991) [Pubmed]
  16. Bovine adrenal cortex transformations of mitotane [1-(2-chlorophenyl)-1-(4-chlorophenyl)-2,2-dichloroethane; o,p'-DDD] and its p,p'- and m,p'-isomers. Cai, W., Benitez, R., Counsell, R.E., Djanegara, T., Schteingart, D.E., Sinsheimer, J.E., Wotring, L.L. Biochem. Pharmacol. (1995) [Pubmed]
  17. Molecular and pharmacological evidence for modulation of kinin B(1) receptor expression by endogenous glucocorticoids hormones in rats. Cabrini, D.A., Campos, M.M., Tratsk, K.S., Merino, V.F., Silva , J.A., Souza, G.E., Avellar, M.C., Pesquero, J.B., Calixto, J.B. Br. J. Pharmacol. (2001) [Pubmed]
  18. A patient with adrenocortical carcinoma: characterization of its biological activity and drug resistance profile. Feller, N., Hoekman, K., Kuiper, C.M., Linn, S.C., Verheul, H.M., Wolthers, B.G., Popp-Snijders, C., Pinedo, H.M. Clin. Cancer Res. (1997) [Pubmed]
  19. Cytochrome P450-catalyzed binding of 3-methylsulfonyl-DDE and o,p'-DDD in human adrenal zona fasciculata/reticularis. Lindhe, O., Skogseid, B., Brandt, I. J. Clin. Endocrinol. Metab. (2002) [Pubmed]
  20. Mitotane (1-(o-chlorophenyl)-1-(p-chlorophenyl)-2,2-dichloroethane) metabolism in perfusion studies with dog adrenal glands. Sinsheimer, J.E., Freeman, C.J. Drug Metab. Dispos. (1987) [Pubmed]
  21. The in vitro metabolism of 1-(o-chlorophenyl)-1-(p-chlorophenyl)-2,2-dichloroethane (o,p'-DDD) by dog adrenal mitochondria and metabolite covalent binding to mitochondrial macromolecules: a possible mechanism for the adrenocorticolytic effect. Martz, F., Straw, J.A. Drug Metab. Dispos. (1977) [Pubmed]
  22. Virilizing adrenal tumor in a child suppressed with dexamethasone for three years. Effect of o,p'-DDD on serum and urinary androgens. Korth-Schutz, S., Levine, L.S., Roth, J.A., Saenger, P., New, M.I. J. Clin. Endocrinol. Metab. (1977) [Pubmed]
  23. Identification of environmental chemicals with estrogenic activity using a combination of in vitro assays. Klotz, D.M., Beckman, B.S., Hill, S.M., McLachlan, J.A., Walters, M.R., Arnold, S.F. Environ. Health Perspect. (1996) [Pubmed]
  24. The organochlorine o,p'-DDD disrupts the adrenal steroidogenic signaling pathway in rainbow trout (Oncorhynchus mykiss). Lacroix, M., Hontela, A. Toxicol. Appl. Pharmacol. (2003) [Pubmed]
  25. Comparison of the adrenalytic activity of mitotane and a methylated homolog on normal adrenal cortex and adrenal cortical carcinoma. Schteingart, D.E., Sinsheimer, J.E., Counsell, R.E., Abrams, G.D., McClellan, N., Djanegara, T., Hines, J., Ruangwises, N., Benitez, R., Wotring, L.L. Cancer Chemother. Pharmacol. (1993) [Pubmed]
  26. The effect of o,p'-DDD on adrenal steroid replacement therapy requirements. Robinson, B.G., Hales, I.B., Henniker, A.J., Ho, K., Luttrell, B.M., Smee, I.R., Stiel, J.N. Clin. Endocrinol. (Oxf) (1987) [Pubmed]
  27. Prospective evaluation of mitotane toxicity in adrenocortical cancer patients treated adjuvantly. Daffara, F., De Francia, S., Reimondo, G., Zaggia, B., Aroasio, E., Porpiglia, F., Volante, M., Termine, A., Di Carlo, F., Dogliotti, L., Angeli, A., Berruti, A., Terzolo, M. Endocr. Relat. Cancer (2008) [Pubmed]
  28. Plasma calcitonin and ACTH responses to lysine vasopressin, calcium and pentagastrin in a patient with medullary thyroid carcinoma associated with Cushing's syndrome. Shimatsu, A., Kato, Y., Tanaka, I., Nakai, Y., Fukunaga, M., Imura, H. Clin. Endocrinol. (Oxf) (1983) [Pubmed]
  29. Evaluation of chemicals with endocrine modulating activity in a yeast-based steroid hormone receptor gene transcription assay. Gaido, K.W., Leonard, L.S., Lovell, S., Gould, J.C., Babaï, D., Portier, C.J., McDonnell, D.P. Toxicol. Appl. Pharmacol. (1997) [Pubmed]
  30. Evaluation of plasma insulin-like growth factor binding protein-2 as a marker for adrenocortical tumors. Boulle, N., Baudin, E., Gicquel, C., Logié, A., Bertherat, J., Penfornis, A., Bertagna, X., Luton, J.P., Schlumberger, M., Le Bouc, Y. Eur. J. Endocrinol. (2001) [Pubmed]
  31. A six month mitotane course induced sustained correction of hypercortisolism in a young woman with PPNAD and Carney complex. Cignarelli, M., Picca, G., Campo, M., Margaglione, M., Marino, A., Logoluso, F., Giorgino, F. J. Endocrinol. Invest. (2005) [Pubmed]
  32. Mitotane associated with cisplatin, etoposide, and doxorubicin in advanced childhood adrenocortical carcinoma: mitotane monitoring and tumor regression. Zancanella, P., Pianovski, M.A., Oliveira, B.H., Ferman, S., Piovezan, G.C., Lichtvan, L.L., Voss, S.Z., Stinghen, S.T., Callefe, L.G., Parise, G.A., Santana, M.H., Figueiredo, B.C. J. Pediatr. Hematol. Oncol. (2006) [Pubmed]
  33. Sustained remission of Cushing's disease with mitotane and pituitary irradiation. Schteingart, D.E., Tsao, H.S., Taylor, C.I., McKenzie, A., Victoria, R., Therrien, B.A. Ann. Intern. Med. (1980) [Pubmed]
  34. Mitotane enhances cytotoxicity of chemotherapy in cell lines expressing a multidrug resistance gene (mdr-1/P-glycoprotein) which is also expressed by adrenocortical carcinomas. Bates, S.E., Shieh, C.Y., Mickley, L.A., Dichek, H.L., Gazdar, A., Loriaux, D.L., Fojo, A.T. J. Clin. Endocrinol. Metab. (1991) [Pubmed]
  35. Clinical review: Adrenocortical carcinoma: clinical update. Allolio, B., Fassnacht, M. J. Clin. Endocrinol. Metab. (2006) [Pubmed]
WikiGenes - Universities